Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$3.74 +4.2%	$4.24	$2.30 ▼ $30.34	$15.94M	1.15	39,304 shs	51,310 shs
HOTH Hoth Therapeutics	$1.30 +0.8%	$1.29	$0.65 ▼ $3.80	$17.24M	0.66	233,599 shs	151,135 shs
MTEX Mannatech	$8.52 +0.2%	$8.68	$7.05 ▼ $16.49	$15.84M	0.84	21,579 shs	6,051 shs
SLXN Silexion Therapeutics	$7.18 +5.6%	$10.88	$6.51 ▼ $236.25	$5.25M	0.08	150,449 shs	26,166 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	0.00%	+0.81%	-17.07%	+2.19%	-87.36%
HOTH Hoth Therapeutics	0.00%	+1.56%	0.00%	+52.22%	+85.58%
MTEX Mannatech	0.00%	-6.43%	+5.06%	-13.55%	+21.64%
SLXN Silexion Therapeutics	0.00%	-1.24%	-43.15%	-53.97%	+717,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLRX BioLineRx	3.3871 of 5 stars	3.8	5.0	2.5	0.0	1.3
HOTH Hoth Therapeutics	2.4541 of 5 stars	3.5	5.0	1.0	0.0	0.6
MTEX Mannatech	0.2724 of 5 stars	0.0	3.0	0.6	1.7	0.0
SLXN Silexion Therapeutics	1.4721 of 5 stars	3.5	0.0	2.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	3.50	Strong Buy	$26.00	595.19% Upside
HOTH Hoth Therapeutics	3.00	Buy	$4.00	207.69% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A
SLXN Silexion Therapeutics	3.00	Buy	$75.00	944.57% Upside

Current Analyst Ratings Breakdown

Latest SLXN, HOTH, MTEX, and BLRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/17/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/30/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/28/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$28.94M	0.55	N/A	N/A	$4.04 per share	0.93
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
MTEX Mannatech	$117.87M	0.14	$2.18 per share	3.90	$4.57 per share	1.86
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	($37.31) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$9.22M	-$8.80	N/A	N/A	N/A	-45.34%	-49.74%	-17.54%	N/A
HOTH Hoth Therapeutics	-$8.19M	-$1.07	0.00	N/A	N/A	N/A	-114.32%	-105.92%	11/11/2025 (Estimated)
MTEX Mannatech	$2.49M	-$2.04	0.00	∞	N/A	-3.46%	-48.60%	-10.70%	11/10/2025 (Estimated)
SLXN Silexion Therapeutics	-$16.44M	N/A	0.00	∞	N/A	N/A	N/A	-355.74%	9/4/2025 (Estimated)

Latest SLXN, HOTH, MTEX, and BLRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BLRX BioLineRx	-$0.35	-$1.00	-$0.65	-$1.00	$0.66 million	$0.30 million
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/12/2025	Q2 2025	MTEX Mannatech	N/A	-$2.27	N/A	-$2.27	N/A	$25.68 million
8/12/2025	Q2 2025	SLXN Silexion Therapeutics	-$3.15	-$4.32	-$1.17	-$4.32	N/A	N/A
5/27/2025	Q1 2025	BLRX BioLineRx	-$0.84	$1.39	+$2.23	$1.39	$7.72 million	$11.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.33	2.06	1.87
HOTH Hoth Therapeutics	N/A	27.54	27.54
MTEX Mannatech	0.58	1.11	0.49
SLXN Silexion Therapeutics	26.58	2.44	2.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
HOTH Hoth Therapeutics	7.08%
MTEX Mannatech	12.98%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
HOTH Hoth Therapeutics	6.92%
MTEX Mannatech	41.50%
SLXN Silexion Therapeutics	6.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	40	4.26 million	4.22 million	Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
MTEX Mannatech	250	1.90 million	1.11 million	Not Optionable
SLXN Silexion Therapeutics	N/A	730,000	688,000	N/A

SLXN, HOTH, MTEX, and BLRX Headlines

Recent News About These Companies

Silexion Therapeutics Executes Reverse Stock Split

August 22 at 9:57 PM | msn.com

Silexion Therapeutics Increases Authorized Share Capital

August 19, 2025 | tipranks.com

Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025 | finanznachrichten.de

Silexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven Cancers

August 12, 2025 | quiverquant.comQ

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | globenewswire.com

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

July 31, 2025 | globenewswire.com

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

July 31, 2025 | globenewswire.com

Silexion Therapeutics Holds Annual General Meeting

July 17, 2025 | theglobeandmail.com

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

July 16, 2025 | globenewswire.com

Silexion Therapeutics Corp. Reports Positive Preclinical Data for ...

July 11, 2025 | nasdaq.com

Silexion Therapeutics Announces Positive Results in Preclinical Study ...

July 11, 2025 | morningstar.comM

Silexion Therapeutics receives Nasdaq panel approval for continued listing

July 9, 2025 | uk.investing.com

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

July 9, 2025 | globenewswire.com

Silexion Therapeutics announces preclinical results on SIL204

May 30, 2025 | finance.yahoo.com

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

May 30, 2025 | msn.com

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

May 29, 2025 | finance.yahoo.com

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers

May 23, 2025 | nasdaq.com

Silexion Therapeutics Receives Nasdaq Delisting Notice

May 23, 2025 | tipranks.com

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025 | globenewswire.com

Silexion Therapeutics Corporation Registered Shs

May 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, HOTH, MTEX, and BLRX Company Descriptions

BioLineRx NASDAQ:BLRX

$3.74 +0.15 (+4.18%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.75 +0.01 (+0.29%)

As of 08/22/2025 07:50 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Hoth Therapeutics NASDAQ:HOTH

$1.30 +0.01 (+0.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.26 -0.04 (-2.69%)

As of 08/22/2025 07:59 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Mannatech NASDAQ:MTEX

$8.52 +0.02 (+0.18%)

Closing price 08/22/2025 03:45 PM Eastern

Extended Trading

$8.48 -0.04 (-0.47%)

As of 08/22/2025 04:38 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

Silexion Therapeutics NASDAQ:SLXN

$7.18 +0.38 (+5.59%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$6.88 -0.30 (-4.23%)

As of 08/22/2025 07:56 PM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time